巴西南部阿雷格里港新近诊断成人HIV-1基因多样性与整合酶链转移抑制剂传播性耐药
研究对巴西南部42例未接受抗逆转录病毒治疗的HIV-1感染者进行整合酶基因RT-PCR扩增和测序,评估HIV-1基因多样性和针对整合酶链转移抑制剂(INSTI)的传播性耐药突变。未检出INSTI传播性耐药突变,L74M和L74I多态性各占4.8%。亚型以C型(50%)最常见,其次为BC重组型(21%)和B型(19%),并首次报告F1型(4.8%)和CF1重组型(4.8%)。
要点
- 42例未治疗感染者中未检出针对INSTI的传播性耐药突变。
- 辅助性多态性L74M和L74I各占4.8%,仅在伴其他主要突变时才与雷特格韦耐药相关。
- 亚型分布以C型50%、BC重组型21%、B型19%为主,另见F1型和CF1重组型各4.8%。
核心结论
- 42例未接受抗逆转录病毒治疗的个体均似乎对INSTI敏感,INSTI自2009年起纳入巴西治疗指南。
- 据作者所知,这是巴西首个评估针对INSTI的传播性耐药突变的研究。
- 最流行的HIV-1亚型为C型,其次为BC重组型和B型,与既往研究一致;但本文报告的F1型和CF1重组型在既往研究中未观察到。
研究设计与样本
- 研究对来自巴西南部的42例未接受抗逆转录病毒治疗的HIV-1感染者样本进行病毒RNA提取,经RT-PCR扩增完整HIV-1整合酶基因并测序。
主要发现
- 本研究中未检出携带针对INSTI的传播性耐药突变的病毒株。
- 多态性L74M和L74I各在4.8%的个体中观察到,这些辅助性突变据报道仅在合并其他主要突变时才可能导致雷特格韦治疗中的传播性耐药突变。
- HIV-1亚型分析显示50%为C型、21%为BC重组型、19%为B型、4.8%为F1型、4.8%为CF1重组型。
关键数值与推荐
- L74M和L74I多态性各占4.8%(42例中的相应个体)。
- 亚型构成:C型50%、BC重组型21%、B型19%、F1型4.8%、CF1重组型4.8%。
临床怎么用
- 作者结论为42例未治疗个体均似乎对INSTI敏感,INSTI自2009年起纳入巴西治疗指南;原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The HIV-1 genetic diversity and the presence of transmitted drug resistance mutations (TDRMs) against integrase strand transfer inhibitors (INSTIs) were assessed sequencing samples of antiretroviral (ARV)-naive HIV-1-infected individuals from South Brazil. METHODS: Viral RNA from 42 ART-naive individuals was submitted to complete HIV-1 integrase gene amplification by RT-PCR and sequencing. RESULTS: Viral strains carrying TDRMs against INSTIs were not detected in the present study. However, the polymorphisms L74M and L74I were each observed in 4.8% of the individuals. These accessory mutations have been reported as putative causes of TDRMs in ART with raltegravir, but only when associated with additional major mutations. When submitted to HIV-1 subtyping, 50% were classified as subtype C, 21% as recombinant BC, 19% as subtype B, 4.8% as subtype F1 and 4.8% as recombinant CF1. CONCLUSIONS: All 42 ARV-naive individuals were apparently susceptible to INSTIs, included in the Brazilian therapeutic guideline since 2009. To the best of our knowledge, this is the first study to evaluate TDRMs against INSTIs in Brazil. The most prevalent HIV-1 subtypes were subtype C, followed by the recombinant BC and subtype B, which is in agreement with previous studies. However, the presence of subtype F1 and recombinant CF1 reported herein was not observed in previous studies.
引用
- Nunes CC, Sita A, Mallmann L, et al. HIV-1 genetic diversity and transmitted drug resistance to integrase strand transfer inhibitors among recently diagnosed adults in Porto Alegre, South Brazil. J Antimicrob Chemother. 2022. PMID: 36272141. doi:10.1093/jac/dkac355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。